<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092362</url>
  </required_header>
  <id_info>
    <org_study_id>HDZNRW-KA-009-HO</org_study_id>
    <nct_id>NCT03092362</nct_id>
  </id_info>
  <brief_title>Beat-to-beat Variability in Persistent Atrial Fibrillation</brief_title>
  <acronym>BVAR-Afib</acronym>
  <official_title>Beat-to-beat Variability in Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart and Diabetes Center North-Rhine Westfalia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart and Diabetes Center North-Rhine Westfalia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart rate variability (HRV) in patients with atrial fibrillation (AF) is hardly studied.&#xD;
      Though a reduced HRV in patients with heart failure and reduced ejection fraction (HFrEF) has&#xD;
      been associated with poor prognosis. Data on HRV in AF-patients without a reduced ejection&#xD;
      fraction is lacking. We hypothesize that those patients with persistent atrial fibrillation&#xD;
      and larger beat-to-beat variability would be more symptomatic than does those with smaller&#xD;
      HRV. To asses this theory we intend to perform a prospective observational trial. Symptoms of&#xD;
      Atrial fibrillation will be assessed using Quality of Life questionnaires and 6 minutes&#xD;
      walking test. Heart rate variability will be assessed using 24 hour Holter ECG monitoring.&#xD;
&#xD;
      The correlation between symptoms and heart rate variability will be then assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation symptoms</measure>
    <time_frame>7 days</time_frame>
    <description>Whether atrial fibrillation symptoms assessed by Quality-of-Life questionnaires correlates with heart rate variability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation symptoms</measure>
    <time_frame>7 days</time_frame>
    <description>Whether atrial fibrillation symptoms assessed by Quality-of-Life questionnaires correlates with heart rate reserve. Heart rate reserve is defined as the difference between maximal heart rate (220- age in years) and mean heart rate during atrial fibrillation (assessed by 24 hour Holter ECG monitoring).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in 6MWD (6 minutes walk distance)</measure>
    <time_frame>7 days</time_frame>
    <description>Whether 6MWD improvement after treatment of atrial fibrillation correlates with heart rate variability.</description>
  </secondary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with persistent atrial fibrillation (defined as lasting more than seven days or&#xD;
        requiring termination by cardioversion either with drugs or by direct current&#xD;
        cardioversion) who are admitted at our clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent atrial fibrillation&#xD;
&#xD;
          -  No previous ablation for atrial fibrillation&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  Signed written patient's informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Paroxysmal atrial fibrillation&#xD;
&#xD;
          -  Previous ablation therapy for atrial fibrillation&#xD;
&#xD;
          -  Reduced left ventricular ejection fraction (LVEF&lt;35%)&#xD;
&#xD;
          -  Permanent ventricular pacing (including cardiac resynchronization therapy CRT)&#xD;
&#xD;
          -  Acute coronary syndrome (ACS) during past 6 weeks.&#xD;
&#xD;
          -  Stroke or TIA within past 6 weeks.&#xD;
&#xD;
          -  Cardiac surgical operation/ intervention within past 3 months.&#xD;
&#xD;
          -  Acute decompensated heart failure&#xD;
&#xD;
          -  Treatment with IV Inotropic medications (e.g. Dobutamine, Levosimendan)&#xD;
&#xD;
          -  Mitral valve replacement or rheumatic mitral valve stenosis&#xD;
&#xD;
          -  Neurological or psychological disease that may impair patient's judgement or&#xD;
             compliance&#xD;
&#xD;
          -  Pregnancy or Breast-feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hazem Omran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HDZ NRW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart and Diabetes Center NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>North Rhine Westphalia</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Cygankiewicz I, Corino V, Vazquez R, Bayes-Genis A, Mainardi L, Zareba W, de Luna AB, Platonov PG; MUSIC Trial Investigators. Reduced Irregularity of Ventricular Response During Atrial Fibrillation and Long-term Outcome in Patients With Heart Failure. Am J Cardiol. 2015 Oct 1;116(7):1071-5. doi: 10.1016/j.amjcard.2015.06.043. Epub 2015 Jul 16.</citation>
    <PMID>26298305</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>persistent atrial fibrillation</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

